Donanemab In Medicare: Quick Reversal Of Alzheimer’s Coverage Limits Doubtful, Lilly Says
Executive Summary
Lilly execs caution that even if FDA approves donanemab in 2023, no uptake of any significance is expected until 2024 and beyond. An accelerated approval would essentially preclude Medicare reimbursement, and a CMS policy change or more persuasive trial data could take some time.
You may also be interested in...
Medicare Coverage For Alzheimer’s Drugs: CMS Declines To Revise Restrictions For Class
Medicare coverage restrictions are more likely to be reconsidered on a case-by-case basis as drugs in the class obtain traditional US Food and Drug Administration approvals in the coming months.
US FDA Rejects Lilly’s Bid For Donanemab Accelerated Approval In Early Alzheimer’s
More long-term data for donanemab needed, FDA says. Lilly plans to seek traditional approval for its amyloid-clearing antibody after the Phase III TRAILBLAZER-ALZ 2 trial reads out in Q2, but it loses important ground in reimbursement negotiations.
Medicare Weighing National Part B Coverage For ViiV’s HIV PrEP Apretude As ‘Preventive Service’
Unusual national coverage determination for a prevention-only drug was opened in response to a formal request from ViiV for its long-acting injectable.